Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.53 |
| ▸ | MAOA | P21397 | 6/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102245 | 0.84 | MAOB (0.71) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL9110245 | 0.79 | MAOB (0.50) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL30842883 | 0.78 | PTPN1 (0.75) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL96940 | 0.78 | PTPN1 (0.75) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL8051158 | 0.78 | MAOB (0.53) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL12903098 | 0.75 | MAOB (0.50) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL19275439 | 0.75 | MAOB (0.50) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL9113323 | 0.75 | MAOB (0.46) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL5689431 | 0.74 | MAOB (0.75) | MAOBMAOAPTPN1ALDH1A1MAPT | |
| SCHEMBL20509363 | 0.74 | ALDH1A1 (0.55) | MAOBMAOAPTPN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621115-B | Method for synthesizing oxime compounds under photocatalysis condition | 河南大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-114621115-A | Method for synthesizing oxime compound under photocatalysis condition | 河南大学 | 2022-06-14 | — | — | CN | disclosed |
| WO-2015014791-A1 | BENZIMIDAZOLO[2,1-B][1,3]BENZOTHIAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-20100247938-A1 | MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100247938-A1 | MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20070152569-A1 | Novel benzo[b]furan derivatives and their use | WELL-BEING BIOCHEMICAL CORP. | 2007-07-05 | — | — | US | disclosed |
| US-6300340-B1 | USEFUL FOR THERAPY OF CANCER AND SOLID TUMORS | ADIR ET COMPAGNIE (FR) | 2001-10-09 | — | — | US | disclosed |
| US-6162822-A | Bisimide compounds | ADIR ET COMPAGNIE (FR) | 2000-12-19 | — | — | US | disclosed |
| EP-0820985-B1 | Bis imide derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-08-30 | — | — | EP | disclosed |
| US-5854273-A | Bisimide compounds | ADIR ET COMPAGNIE (FR) | 1998-12-29 | — | — | US | disclosed |
| EP-0820985-A1 | Bis imide derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070152569-A1 | Novel benzo[b]furan derivatives and their use | JUND, FOSB, BRD9 | MAOB 10/4885MAOA 305/4885PTPN1 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.